(Reuters) – Seagen Inc said on Friday an arbitrator had ruled in favor of Japan’s Daiichi Sankyo over an agreement between the two companies for using Seagen’s drug technology.
A Texas jury in April awarded Seagen nearly $42 million from Daiichi Sankyo over claims that Daiichi and AstraZeneca plc’s breast-cancer drug Enhertu violated Seagen’s patent rights.
(Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)
